Skip to main content

Table 1 Patient characteristics (n = 10)

From: Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer

Gender, n (%)

 

Male

0 (0)

Female

10 (100)

Age

 

Median, years (range)

61 (34–70)

ECOG PS, n (%)

 

0

6 (60)

1

4 (40)

Histological subtype, n (%)

 

Ductal carcinoma

8 (80)

Lobular carcinoma

2 (20)

Liver metastases

 

Yes

6 (60)

No

4 (40)

Stage, n (%)

 

Locally advanced

1 (10)

Metastatic

9 (90)

Prior line(s) of chemotherapy, n (%)

 

1

1 (10)

2

1 (10)

> 2

8 (80)